title: Second-line treatment of postmenopausal women with advanced breast carcinoma.
abstract: Breast cancer is the most prevalent cancer in women and, currently, there is no standard of care for the treatment of metastatic disease. Treatment options are based on a number of tumor- and patient-related factors. This review explores some of these options, including the use of hormonal manipulation in the treatment of hormone-positive disease, current chemotherapy options and the use of targeted therapies, such as trastuzumab.
authors.affiliation: Cancer Research UK Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. ruth.board@christie-tr.nwest.nhs.uk
authors.forename: Ruth E
authors.initials: RE
authors.lastname: Board
authors.forename: Emma J
authors.initials: EJ
authors.lastname: Dean
authors.forename: Claire
authors.initials: C
authors.lastname: Mitchell
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Wardley
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D005260:Female; D006801:Humans; D017698:Postmenopause / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal